MIR Industrial Technology · Nuclear · Radiation safety · Medical devices · Thesis updated August 5, 2026

Nuclear backlog hits record but organic growth slows

Q2 2026 backlog reached a record $1.14 billion as nuclear power demand continued to accelerate.
Total revenue grew 20% to $266.8 million, but organic growth was a soft 1%.
Nuclear and Safety made up 69.8% of Q2 revenue, widening its lead as the primary growth engine.
Operating margins expanded by 150 basis points due to better pricing and product mix.
The Medical segment remains sluggish, increasing pressure on new AI product launches to spark a recovery.

01 Running thesis

Strong nuclear demand meets medical drag

Mirion is riding a clear wave of nuclear power investment. In Q2 2026, the company reported a record $1.14 billion backlog. Management cited three waves driving this demand: deferred maintenance catch-up, plant life extensions, and digital transformation. Total revenue grew 20% year over year to $266.8 million, heavily supported by the Paragon and Certrec acquisitions.

The bull case focuses on this nuclear visibility. With nearly 70% of revenue now coming from the Nuclear and Safety segment, Mirion has deep roots in a highly regulated and growing market. The company also expanded adjusted EBITDA margins by 150 basis points to 24.5% in the second quarter, proving it can pass along price increases and improve product mix.

The bear case centers on soft core growth and lagging medical sales. Overall organic revenue growth was just 1% in Q2 2026. The Medical segment continues to struggle with weak volumes. The company is leaning on new AI software tools like PlanAI to fix this, but success is not guaranteed. Mirion also faces a complex capital structure with $775 million in convertible notes and growing geopolitical trade friction.

Jul 2026→Q2 2026 backlog reached a record $1.14 billion, up nearly 40%. However, overall organic revenue growth was a soft 1% due to sluggishness in the Medical segment.

Apr 2026▲Q1 orders grew 42% including acquisitions and backlog reached a record $1.1 billion. Paragon also grew revenue 45%, which strengthened the nuclear growth case.

Apr 2026→The Q1 2026 filing showed the tradeoff behind the growth. Nuclear & Safety revenue rose 39%, but operating margin fell to 11.3% because recent acquisitions added costs and amortization.

Feb 2026▼The 2025 Form 10-K added a clearer SMR risk and confirmed $775 million of convertible notes issued in 2025. The nuclear opportunity grew, but the capital structure became more complex.

Feb 2026▲Full-year 2025 results showed record orders of more than $1 billion and a large project pipeline above $400 million. Medical and labs weakness kept the view from becoming fully positive.

Oct 2025▲Management said year-to-date SMR orders had passed the prior two years combined. That supported the nuclear demand case, while U.S. RTQA softness added a new watch item.

Oct 2025→Mirion announced plans to buy Paragon for about $585 million, funded with equity and convertible debt. The deal deepened nuclear exposure but raised integration and dilution risk.

Aug 2025▲Q2 2025 revenue grew 7.6% and the company returned to GAAP profitability. A $400 million convertible note refinancing extended maturities and improved flexibility.

02 Business model

Critical tools for regulated customers

Mirion makes money by selling radiation detection, measurement, monitoring, and safety systems. Its customers include nuclear power plants, defense agencies, research labs, hospitals, and cancer-care centers. These buyers care about safety, approvals, and reliability, making it hard for them to switch suppliers.

The business has two main types of revenue. One is recurring flow work, such as replacements, service, dosimetry badges, and software tied to a large installed base. The other is larger project work, such as new plant systems, reactor upgrades, and small modular reactor orders. Project work is valuable, but the timing can be uneven.

Paragon and Certrec pushed Mirion deeper into the nuclear plant life cycle. Certrec helps with licensing and regulatory needs. Paragon helps with obsolescence, parts availability, and engineered solutions. That broader offer helps Mirion win more work, but it also raised the cost and risk of integration.

Medical gives the company a second lane. It sells quality assurance tools for radiation therapy, nuclear medicine equipment, dosimetry services, and newer AI software. This segment was a drag on recent growth, so a lasting recovery is essential for overall margin targets.

03 Product portfolio

Radiation tools across two markets

Growth engine

Nuclear detection and monitoring

These systems help nuclear sites detect, measure, and monitor radiation. Demand is rising as utilities extend plant lives and plan new reactor projects.

Growth engine

Paragon engineered nuclear solutions

Paragon adds safety-related systems, replacement parts, and obsolescence support. This business serves large-scale reactors and emerging small modular reactors.

Steady

Certrec regulatory compliance

Certrec helps nuclear customers with plant licensing and ongoing regulatory work. This makes Mirion useful earlier in a plant's life cycle.

Steady

Defense and research instruments

Mirion sells radiation detection and identification tools to defense, labs, and research customers. This work adds breadth beyond commercial nuclear power.

Option

Radiation Therapy Quality Assurance

RTQA products help make radiation cancer treatment safer and more accurate. New platforms like Daily QA4 Pro aim to boost sluggish hardware sales.

Cash cow

Nuclear medicine and dosimetry

This area includes dose calibrators, software platforms, and personal radiation monitoring services. It supports hospitals and care teams that work around radiation.

Option

AI and oncology software

Mirion is pushing new AI tools like the PlanAI dosimetry platform. These aim to improve workflow, but AI also brings legal, compliance, and competitive risks.

04 Business segments

Q2 mix shifted further toward nuclear

Nuclear & Safety70%growing fast

Medical30%flat

Segment shares use Q2 2026 revenue from Mirion's Form 10-Q: Nuclear & Safety generated 69.8% of revenue and Medical generated 30.2%.

05 Risk factors

What can break the story

Medical segment sluggishness

Medium impact · High odds

Organic growth was heavily muted at 1% overall in Q2 2026, largely due to ongoing challenges in the Medical segment. If new product launches like PlanAI and Daily QA4 Pro fail to gain traction, the segment will continue to drag on company-wide growth.

We watchMedical segment organic revenue growth and RTQA hardware volume.

Deals add sales but limit profit

High impact · Medium odds

Paragon and Certrec have lifted revenue and orders, but integrating them has pressured operating margins. If synergies arrive slowly or integration causes operational hiccups, the growth story may look expensive.

We watchNuclear & Safety operating margin and acquisition-related costs over the next four quarters.

SMR orders take longer to convert

High impact · Medium odds

Mirion's growth plan depends in part on SMRs, which are small modular reactors that remain an emerging market. The company has order momentum, but SMR customers still face design, regulatory, financing, and buildout risks.

We watchNew SMR awards, customer project delays, and the margin profile of SMR backlog.

China localization and trade friction

Medium impact · Medium odds

China is expanding localization requirements that could force Mirion to localize manufacturing or source local components. Compliance could increase costs, delay sales, and reduce demand for its equipment in Asia.

We watchInternational revenue growth, specific commentary on Chinese localization, and tariff impacts.

Convertible notes dilute owners

Medium impact · Medium odds

Mirion issued $775 million of convertible notes in 2025. Convertible notes are debt that can later turn into stock under certain conditions. This helps fund growth today, but it can also dilute current shareholders if the share count rises.

We watchNet debt, interest expense, conversion triggers, and diluted share count.

06 Quick answers

In one breath

What does Mirion Technologies do?

Mirion sells radiation detection, monitoring, measurement, and safety products. Its main customers are nuclear power plants, defense agencies, research labs, hospitals, and cancer-care providers.

Why is nuclear important to Mirion?

Nuclear and Safety made up 69.8% of Q2 2026 revenue. The segment is also where orders are growing fastest after the Paragon and Certrec acquisitions, driven by plant life extensions and digital upgrades.

What is the biggest risk for Mirion stock?

A key risk is that strong nuclear orders fail to translate into high profits due to integration costs, or that the Medical segment fails to recover from ongoing sluggish demand.

Is Mirion only a nuclear company?

No. Medical made up 30.2% of Q2 2026 revenue and includes radiation therapy quality assurance, nuclear medicine, dosimetry, and oncology software. Still, the company is highly tied to the nuclear industry.